Aim immunotech's subsidiary receives orphan medicinal product designation by the european medicines agency for ampligen to treat pancreatic cancer

Ocala, fla., feb. 24, 2021 (globe newswire) -- aim immunotech inc. (nyse american: aim) today announced that its subsidiary, nv hemispherx biopharma europe, has received formal notification from the european commission (ec) approving the company's orphan medicinal product application for ampligen as a treatment for pancreatic cancer.
AIM Ratings Summary
AIM Quant Ranking